Tango Therapeutics, Inc. (TNGX) Financials
Key financial figures for Tango Therapeutics, Inc. (Q2 2026).
Tango Therapeutics reported a Q2 2026 net loss of $55.3 million as R&D and G&A spend ramped ahead of a planned front-line pancreatic cancer Phase 3 program, closing the quarter with just over $1.0 billion in cash, equivalents, and marketable securities. Q2 2026 net loss was $55.3 million ($0.37 per share), up from a $38.9 million net loss ($0.35 per share) in Q2 2025 R&D expense rose to $37.2 million (from $32.8 million in Q2 2025), driven by continued investment in the vopimetostat and TNG456 clinical programs G&A expense rose to $22.6 million (from $11.3 million in Q2 2025), driven primarily by personnel costs including share-based compensation No collaboration revenue was recognized in Q2 2026 (also $0 in Q2 2025 comparison quarter for the recurring collaboration line; the FY2025 collaboration revenue was a one-time Gilead termination paym. Figures are for Q2 2026, as Tango Therapeutics Inc. reported them.
- Revenue
- $0
- Net Income
- -$55M
- EPS
- $-0.37
- Total Assets
- $1.1B
- Operating Cash Flow
- -$39M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$55M | -$0.37 | -$39M | |
| Q1 FY2026 | $0 | -$46M | -$0.32 | -$44M | |
| Q4 FY2025 | $0 | -$39M | -$0.30 | -$30M | |
| Q3 FY2025 | $54M | $16M | $0.14 | 26.15% | -$31M |
| Q2 FY2025 | $3M | -$39M | -$0.35 | -1287.87% | -$37M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $62M | -$102M | -$0.87 | -178.39% | -$140M |
| FY2024 | $42M | -$130M | -$1.19 | -346.09% | -$132M |
| FY2023 | $37M | -$102M | -$1.08 | -312.57% | -$120M |
Frequently asked questions
What was Tango Therapeutics Inc.'s revenue last quarter?
Tango Therapeutics Inc. reported revenue of $0.00 for Q2 FY2026, down 100.0% from the same period a year earlier.
Is Tango Therapeutics Inc. profitable?
Not in its most recent reported period. Tango Therapeutics Inc. reported a net loss of $55.3 million for Q2 FY2026.
How much free cash flow did Tango Therapeutics Inc. generate?
Tango Therapeutics Inc. generated free cash flow of -$38.9 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Tango Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.